The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
The emergence of new infections in India is a growing concern
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
The robotic surgery program has continually pushed the boundaries of medical technology
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
India Business grew by 11.9% YoY to Rs. 1196.2 crore
The partnership marks a significant milestone in integrating digital health education into medical curricula
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Subscribe To Our Newsletter & Stay Updated